Abstract

Lung cancer is the most common cause of cancer deaths with a limited survival. Most of the cases of lung cancer are non-small cell variety and most of the patients present in advanced stage. After histopathological diagnosis, next step is to document the presence of actionable mutations like EGFR. When positive, EGFR portends sensitivity of the tumor to EGFR TKIs and a better prognosis. We report a case of advanced NSCLC with protracted survival of almost 10 years from the diagnosis of metastatic disease. Patient did present with progressions multiple times but was found to be non-compliant to Erlotinib. Compliance was reinforced every time followed by response on surveillance.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call